MGMT and central nervous system cancer: In Kaplan-Meier survival analyses worse overall survival was observed in patients with increasing age, WHO grade IV glioma, lower Karnofsky Performance Score, incomplete resection or biopsy only, unmethylated MGMT promoter status, absence of IDH mutation and absence of combined radiochemotherapy.